622368-88-1

Basic information

• Product Name: 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[2-(1-METHYL-4-PIPERIDINYL)ETHOXY]-3-QUINOLINECARBONITRILE
• Synonyms: 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[2-(1-METHYL-4-PIPERIDINYL)ETHOXY]-3-QUINOLINECARBONITRILE
• CAS NO: 622368-88-1
• Molecular Formula: C26H28Cl2N4O3
• Molecular Weight: 515.43
• Mol File: 622368-88-1.mol

Chemical Properties

• Boiling Point: 613.1°C at 760 mmHg
• Flash Point: 324.6°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 5.75E-15mmHg at 25°C
• Refractive Index: 1.64
• CAS DataBase Reference: 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[2-(1-METHYL-4-PIPERIDINYL)ETHOXY]-3-QUINOLINECARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[2-(1-METHYL-4-PIPERIDINYL)ETHOXY]-3-QUINOLINECARBONITRILE(622368-88-1)
• EPA Substance Registry System: 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[2-(1-METHYL-4-PIPERIDINYL)ETHOXY]-3-QUINOLINECARBONITRILE(622368-88-1)

Safety Data

• Hazardous Substances Data: 622368-88-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C26H28Cl2N4O3/c1-32-7-4-16(5-8-32)6-9-35-25-12-21-18(10-24(25)34-3)26(17(14-29)15-30-21)31-22-13-23(33-2)20(28)11-19(22)27/h10-13,15-16H,4-9H2,1-3H3,(H,30,31)

Upstream product

• 98446-49-2 2,4-dichloro-5-methoxyaniline 
• 21156-84-3 2-(1-methyl-4-piperidyl)ethanol 
• 622369-46-4 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-fluoro-6-methoxy-3-quinolinecarbonitrile 
• 263149-10-6 4-chloro-7-hydroxy-6-methoxyquinolin-3-carbonitrile 
• 622369-40-8 4-chloro-6-methoxy-7-fluoro-quinoline-3-carbonitrile 
• 366-99-4 3-fluoro-4-methoxyaniline 
• 622369-38-4 7-fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarbonitrile 

Relevant articles and documents

TREATMENT OF IMATINIB RESISTANT LEUKEMIA

The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.

4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Compounds of the formula: wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.

4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML)

Compounds of the formula (I): wherein: n is an integer from 0-3; X is N, CH; R is alkyl of 1 to 3 carbon atoms; R' is 2,4-diCl, 5-OMe in para, ortho, or meta position; 2,4-diCl in para position; 3,4,5-tri-OMe in para position; 2-Cl, 5-OMe in para position

7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as Dual Inhibitors of Src and Abl Kinases

We previously reported that several 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles were potent inhibitors of Src kinase activity. We disclose here a new highly efficient and versatile route to these compounds, which are also potent inhibitors of Abl kina

Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity

Several 7-alkoxy-4-anilino-3-quinolinecarbonitriles were synthesized and evaluated for Src kinase inhibitory activity. Optimal inhibition of both Src enzymatic and cellular activity was seen with analogues having a 2,4-dichloro-5-methoxyaniline group at C-4. Compound 18, which has a 1-methylpiperidinemethoxy group at C-7, showed in vivo activity in a xenograft model.

Process for the preparation of 7-substituted-3 quinolinecarbonitriles

There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-